Fundraising FoxVivtex
Cambridge, US · Founded 2018 · Delaware corporation · 1 known investors
Find your way into Vivtex
Sign up to see every warm intro you have to Vivtex
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Vivtex team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Vivtex is a drug development company applying computational science and pre-clinical research to advance new medicines. It operates in the biotech/therapeutics space, working on drug development and related laboratory research.
Founders & leadership
Vivtex was founded in 2018 by Thomas von Erlach, Robert Langer, and Giovanni Traverso.
TV
Thomas von ErlachCEO & Co-founderHe co-founded Vivtex in 2018 and served as its Chief Scientific Officer until 2026. Before that, he was a postdoctoral fellow in Robert Langer's lab at MIT and held earlier roles at the Oxbridge Biotech Roundtable, A.T. Kearney, and Credit Suisse.
RL
Robert LangerCo-founder
GT
Giovanni TraversoCo-founderHe is a full professor at MIT, an assistant professor at Brigham and Women's Hospital, and an associate member of the Broad Institute of MIT and Harvard. He has also co-founded several biotechnology companies, including Syntis Bio, Absco Therapeutics, and SUTOL Bio.
JW
JAMES WINSCHELNamed on SEC filing
JL
JUAN LOPEZNamed on SEC filing
JB
JACQUES BARBUTNamed on SEC filing
JW
JAMES WRIGHTNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$1.8M disclosed across 1 round · 2022
▶$1.8MraisedAug 2022 · 14 investors · BiotechnologyRule 506(b)
▶$1.8MraisedAug 2022 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- GIOVANNI TRAVERSODirector
- JAMES WINSCHELExecutive Officer, Director
- JUAN LOPEZExecutive Officer
- ROBERT LANGERDirector
- JACQUES BARBUTDirector
- JAMES WRIGHTExecutive Officer
- THOMAS VON ERLACHExecutive Officer, Director
- Offering amount
- $1.8M
- Amount sold
- $1.8M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
EquityZenEquityZen operates an online marketplace that gives accredited individual investors access to shares in late-stage private companies through secondary market transactions. Now part of Morgan Stanley, the platform provides private market data, offering documents, and guided investment processes for buying and selling pre-IPO equity.
Vivace TherapeuticsVivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types. The company adopts a capital-efficient approach to advance novel cancer therapeutics, with potential applications also in fibrotic disease.
Companies working in the same space as Vivtex.
In the news
Frequently asked questions
- What does Vivtex do?
- Vivtex is a drug development company applying computational science and pre-clinical research to advance new medicines. It operates in the biotech/therapeutics space, working on drug development and related laboratory research.
- Who founded Vivtex?
- Vivtex was founded by Thomas von Erlach, Robert Langer, Giovanni Traverso in 2018.
- Who are Vivtex's investors?
- Vivtex's investors include Portal Innovations.
- How much funding has Vivtex raised?
- Vivtex has disclosed $1.8M raised across 1 round.
- Where is Vivtex headquartered?
- Vivtex is headquartered in Cambridge, US.